Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05467670
Title Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
Recruitment Not yet recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Haider Mahdi
Indications

ovary epithelial cancer

Therapies

Doxorubicin + Evorpacept + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field